-
Sector Analysis
Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics. In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData’s epidemiology forecast. Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC. The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drugs In Development, 2024
Empower your strategies with our Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2024 report and make more profitable business decisions. Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen, and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.